As expected, Cempra Inc. initiated Solitaire-IV, its global intravenous (I.V.)-to-oral Phase III trial of solithromycin (CEM-101) before year-end in patients with community-acquired bacterial pneumonia (CABP). The trial, which the company disclosed after Monday’s market close, joins Solitaire-Oral, the first global Phase III study of solithromycin in CABP patients, which initiated enrollment in December 2012. (See BioWorld Today, Dec. 20, 2012.)